news aktuell GmbH

Grünenthal acquires testosterone treatment NebidoTM from Bayer

  • Grünenthal acquires NebidoTM from Bayer AG for up to € 500 million. The product is expected to add about € 100 million to Grünenthal’s EBITDA in 2023.
  • NebidoTM is the gold standard for the treatment ofmale hypogonadism associated with testosterone deficiency. It is available to patients in over 80 markets worldwide.
  • Grünenthal has invested over € 2 billion in successful M&A transactions over the last years, resulting in a significantly strengthened profitability.


Aachen, Germany, 14 July 2022 –Grünenthal, a global science-based, privately-owned pharmaceutical company, today announced an agreement with Bayer AG to acquire NebidoTM, the well-known brand for the treatment of male hypogonadism and its associated brands for up to € 500 million. NebidoTM is the only long-acting injectable treatment for testosterone deficiency. The product is approved and successfully commercialized in over 80 countries. Patent protection exists until March 2024 in the EU and until May 2027 in the US. The brand is expected to add about € 100 million to Grünenthal’s EBITDA in 2023. The acquisition is subject to customary closing conditions, including approval by the relevant competition authorities. Closing is expected to occur by the end of 2022.

“One in six men over 50 live with the symptoms of testosterone deficiency[1]. Too few of these patients receive appropriate treatment[2]. We are committed to facilitating access to treatment for even more patients in need”, says Gabriel Baertschi, Grünenthal CEO. “Grünenthal’s strong track record of acquiring established brands has significantly improved our profitability, allowing us to invest in research and development and create the next generation of pain therapies.”

NebidoTM is the leading brand in the treatment of male hypogonadism. It is used for the treatment of clinical symptoms such as regression of secondary sexual characteristics, change in body composition, asthenia, reduced libido or erectile dysfunction due to low testosterone levels (testosterone deficiency). The product is directly administered by a physician every 10 – 14 weeks. NebidoTM demonstrated a robust safety and efficacy profile backed with solid long-term data.

The acquisition of NebidoTM is part of a series of acquisitions by Grünenthal, including the European rights to CRESTORTM and NexiumTM, the global rights to VimovoTM (ex-US and Japan), the global rights to QutenzaTM and the global rights to ZomigTM (ex-Japan). In 2021, Grünenthal acquired the Swiss biotech company Mestex AG including its innovative investigational medicine resiniferatoxin for the intra-articular treatment of pain associated with osteoarthritis of the knee. Grünenthal has invested over € 2 billion in successful M&A transactions over the past years.

About hypogonadism (testosterone deficiency)

Male hypogonadism due to a reduced or absent secretion of testosterone from the testes is characterized by clinical symptoms such as low libido, erectile dysfunction, asthenia, small testes and decreased muscle mass. These symptoms are sometimes misinterpreted as signs of stress and ageing. In addition to physical symptoms, there can also be psychological symptoms, including depression. One in six men over 50 live with symptomatic androgen deficiency[3]. Only one in ten men between the age of 30 to 79 with symptomatic androgen deficiency receive treatment[4].


About NebidoTM

NebidoTM is the only available injectable long-acting depot preparation of testosterone undecanoate, developed for the treatment of male hypogonadism. NebidoTM is a well-known brand in testosterone therapy. The product is directly administered by a physician every 10 – 14 weeks. NebidoTM demonstrated a robust safety and efficacy profile backed with solid long-term data.

About Grünenthal

Grünenthal is a global leader in pain management and related diseases. As a science-based, fully-integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all of our activities and efforts on working towards our vision of a world free of pain.

Grünenthal is headquartered in Aachen, Germany, and has affiliates in 28 countries across Europe, Latin America and the US. Our products are available in more than 100 countries. In 2021, Grünenthal employed around 4,500 people and achieved sales of € 1.5 bn.

More information:

Click here for our Grünenthal Report 2021/2022

Follow us on:

LinkedIn: Grunenthal Group

Instagram: grunenthal


Fabia Kehren, Head External Communications & Editorial Management

Tel.: +49 241 569-3269

Grünenthal GmbH, 52099 Aachen, Germany

About news aktuell GmbH

news aktuell GmbH
news aktuell GmbH
Mittelweg 144
20148 Hamburg

+49 (0)40 4113-32589

As wholly owned subsidiary of dpa, news aktuell provides business and organizations with effective access to media and consumers. Via the smart tools ots and zimpel, PR content accesses all media formats, including classical print, high click-rate online portals and social networks. In addition, news aktuell publishes all its customers’ PR content on, one of the PR portals with the greatest reach in Germany. By this means, all the relevant multipliers are reached globally, from editors, via digital influencers right up to specialist bloggers and interested consumers. news aktuell has been on the market since 1989. The company, with a staff complement of more than 135, has its headquarters in Hamburg. Other offices are in Berlin, Dusseldorf, Frankfurt und Munich.

Subscribe to releases from news aktuell GmbH

Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from news aktuell GmbH

Kreisel Electric to expand battery production capacities to over 2 GWh22.9.2022 10:10:48 CEST | Press release

Rainbach im Mühlkreis - Deere & Company (NYSE: DE) announced its next steps in meeting the growing demand for batteries as a sole- or hybrid-propulsion system. In addition to the production facility in Austria, John Deere is making an immediate investment in two additional locations to increase the production capacity expansion of Kreisel Electric (“Kreisel”) — the battery technology pioneer in which John Deere recently acquired majority ownership. The significant capital commitment will bring an increase of over 2 GWh to Kreisel battery production capacity, beginning with the opening of a new facility at the John Deere Saran factory — the primary manufacturing location for John Deere engines in the European Union. In parallel with this project, John Deere will also invest in battery assembly in the United States to support the growth of its customers and John Deere products. Find more information here: Kreisel Press Area

TXOne Networks and Valmet to expand their successful OT/ICS cybersecurity services partnership22.9.2022 09:45:00 CEST | Press release

Eindhoven/Tampere, September 22, 2022 — TXOne Networks, a global leader in ICS and industrial IoT (IIoT) security, and Valmet, a leading global developer and supplier of process technologies, automation and services for the pulp, board, paper, tissue, nonwovens, energy, marine and process industries, have announced a partnership. Together they will better equip joint industrial automation customers with the protection they need for today’s vulnerable OT (Operational Technology) environments. The combination of TXOne Networks’s solutions for security inspection, endpoint protection and network defenses with the leading Valmet DNA Distributed Control System (DCS), Valmet IQ Quality Control System (QCS), Machine Vision, Analyzers & Measurements, Valves and Industrial Internet, offers various advantages: It enhances the ability of industrial customers to better protect, respond, and recover from a cybersecurity incident with Valmet’s Cybersecurity Services. As Dr. Terence Liu, CEO of TXOne

China's growing photovoltaic industry may become the preferred choice of the European and American markets21.9.2022 10:33:04 CEST | Press release

Frankfurt, Germany - In the context of climate change, energy crisis and recurring epidemics, the world attaches great importance to sustainable development and low-carbon energy transformation. Driven by breakthroughs of renewable energy and policy tools, the global photovoltaic market maintains a good development trend. In recent years, China's photovoltaic industry has become an important player in the global photovoltaic industry. For the global market, the choice of China's PV supply chain is an extremely favorable move. Insiders believe that the essence of building a community of human destiny can be summarized by "national interests and common prosperity". Countries across the world should deeply understand that their destinies are closely linked to each other, so as to promote mutually beneficial cooperation, give full play to their own advantages, jointly make a larger cooperation cake, and guarantee the right of all countries to pursue prosperity and development. In recent ye

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom